The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

Summary. Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral blood BCR‐ABL/ABL ratio, as assessed by Q‐RT‐PCR, has been shown to correlate with the contemporary cytogenetic response in patients receiving imatinib (Glivec, Gleevec). We have used Q‐RT‐PCR to monitor the early molecular response to 4 weeks and 3 months of imatinib therapy, in 47 patients with established CML. After 4 weeks of imatinib therapy, patients whose BCR‐ABL/ABL ratio had fallen to less than 50% that of baseline had a significantly higher probability of achieving a major cytogenetic response after 6 months of therapy, when compared with those whose ratio did not fall by this amount (P < 0·001). Similarly, patients whose ratio at 3 months was less than 10% of that at baseline had a significantly higher probability of achieving a major cytogenetic remission at 6 months (P < 0·001). Patients who achieved these falls in their BCR‐ABL/ABL ratio at either 4 weeks or 3 months had a superior progression‐free survival at a median follow‐up of 16·5 months (P = 0·01 and 0·003 respectively). These effects were independent of patient age and disease stage. The occurrence of peripheral blood cytopenias sufficiently severe to interrupt therapy was unrelated to progression‐free survival. In conclusion, the data suggest that the early trend in the BCR‐ABL/ABL ratio may be clinically useful for the early identification of patients destined to fare poorly on imatinib.

[1]  R. Clark,et al.  Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia , 2002, British journal of haematology.

[2]  D. Ginzinger Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. , 2002, Experimental hematology.

[3]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[4]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[5]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[6]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[7]  A. Elmaagacli,et al.  Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR‐ABL fusion transcripts detected using a new real‐time polymerase chain reaction method , 2001, British journal of haematology.

[8]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[9]  C. Craddock,et al.  Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2001, Blood.

[10]  P. Vigneri,et al.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.

[11]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[12]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[13]  Shawn M. Sweeney,et al.  Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. , 2000, Blood.

[14]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[15]  Branford,et al.  Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics , 1999, British journal of haematology.

[16]  A. Reiter,et al.  Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR , 1999, Leukemia.

[17]  A. Ganser,et al.  Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation , 1999, Leukemia.

[18]  F. Révillion,et al.  Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay , 1999, Leukemia.

[19]  Schaap,et al.  Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR , 1998, British journal of haematology.

[20]  F. Kwiatkowski,et al.  Interphase cytogenetics and competitive RT‐PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon‐α therapy , 1998, British journal of haematology.

[21]  P. Sherrington,et al.  Molecular status of individual CFU‐GM colonies derived from chemotherapy‐mobilised peripheral blood stem cells in chronic myeloid leukaemia , 1997, Genes, chromosomes & cancer.

[22]  J. Goldman,et al.  Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. , 1996, Blood.

[23]  J. Goldman,et al.  Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. , 1996, Blood.

[24]  J. Goldman,et al.  A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia , 1994, British journal of haematology.

[25]  T. Lion,et al.  Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia , 1993, The Lancet.

[26]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[27]  H. Kantarjian,et al.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.

[28]  C. Herrington,et al.  Interphase cytogenetics , 2004, Neurochemical Research.

[29]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[30]  A. Albertini,et al.  Quantification of bcr/abl mRNA expression by a rapid real-time reverse transcription-polymerase chain reaction assay in patients with chronic myeloid leukemia. , 2001, Haematologica.

[31]  M. Baccarani,et al.  Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. , 2001, Haematologica.

[32]  J. Goldman,et al.  Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission , 2000 .

[33]  J. Goldman,et al.  Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. , 2000, Blood.

[34]  Z. Estrov,et al.  Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? , 1999, Blood.

[35]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[36]  C. Wittwer,et al.  Continuous fluorescence monitoring of rapid cycle DNA amplification. , 1997, BioTechniques.